Cargando…

Once-Monthly Continuous Erythropoietin Receptor Activator (C.E.R.A.) in Patients with Hemodialysis-Dependent Chronic Kidney Disease: Pooled Data from Phase III Trials

INTRODUCTION: Erythropoiesis-stimulating agents and iron are commonly used in patients with chronic kidney disease with the aim of correcting anemia and maintaining stable hemoglobin levels. We analyzed pooled data from 13 studies with similar designs included in the Umbrella Continuous Erythropoiet...

Descripción completa

Detalles Bibliográficos
Autores principales:	Locatelli, Francesco, Choukroun, Gabriel, Truman, Matt, Wiggenhauser, Alfons, Fliser, Danilo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4846713/ https://www.ncbi.nlm.nih.gov/pubmed/26965694 http://dx.doi.org/10.1007/s12325-016-0309-6

Ejemplares similares

Once-monthly continuous erythropoietin receptor activator (CERA) for haemoglobin maintenance in haemodialysis patients with chronic renal anaemia
por: Duman, Neval, et al.
Publicado: (2014)

Effective Achievement of Hemoglobin Stability with Once-Monthly C.E.R.A. in Peritoneal Dialysis Patients: A Prospective Study
por: Koch, Michael, et al.
Publicado: (2013)

Nanomedicines in the treatment of anemia in renal disease: focus on CERA (Continuous Erythropoietin Receptor Activator)
por: Panchapakesan, Usha, et al.
Publicado: (2007)

Efficacy & safety of continuous erythropoietin receptor activator (CERA) in treating renal anaemia in diabetic patients with chronic kidney disease not on dialysis
por: Vankar, Sameer G., et al.
Publicado: (2014)

Epoetin β pegol (continuous erythropoietin receptor activator, CERA) is another choice for the treatment of anemia in myelodysplastic syndrome: a case report
por: Ikenoue, Tatsuyoshi, et al.
Publicado: (2017)

Persona di cera/
por: Tynianov, IU. N. 1894-1943 (IUrii Nikolaevich)

C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis
por: Roger, Simon D., et al.
Publicado: (2011)

Anemia Control in Kidney Transplant Recipients Using Once-Monthly Continuous Erythropoietin Receptor Activator: A Prospective, Observational Study
por: Budde, Klemens, et al.
Publicado: (2014)

El museo de cera
por: Edwards, Jorge
Publicado: (1997)

El museo de cera
por: Edwards, Jorge
Publicado: (1981)

Museo de cera ; manual de exploradores, 1960-1972
por: Alvarez, José María, 1942-
Publicado: (1974)

Hombres con alas de cera /
por: Cruz Oliva, Oscar René
Publicado: (2003)

La cera en México : arte e historia
por: Esparza Liberal, María José
Publicado: (1994)

Santo en el museo de cera
Publicado: (2003)

Anaemia management with C.E.R.A. in routine clinical practice: OCEANE (Cohorte Mircera patients non-dialysés), a national, multicenter, longitudinal, observational prospective study, in patients with chronic kidney disease not on dialysis
por: Frimat, Luc, et al.
Publicado: (2013)

Phase II study of two dose schedules of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in anemic patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy
por: Hirsh, Vera, et al.
Publicado: (2007)

Correction of Anemia with Continuous Erythropoietin Receptor Activator in Korean Patients on Long-Term Hemodialysis
por: Oh, Jieun, et al.
Publicado: (2014)

Cost-Effectiveness and Resource Allocation (CERA) – directions for the future
por: Baltussen, Rob, et al.
Publicado: (2009)

Uso de las ceras en el laboratorio dental /
por: Toral Aburto, Wendy Jessica
Publicado: (2005)

Qairooti (Cerate or Cera Beeswax Salve) in Traditional Iranian Pharmacy
por: Mosleh, Ghazaleh, et al.
Publicado: (2016)

Reticulocyte dynamic and hemoglobin variability in hemodialysis patients treated with Darbepoetin alfa and C.E.R.A.: a randomized controlled trial
por: Forni, Valentina, et al.
Publicado: (2013)

Real-world effectiveness of aripiprazole once-monthly REACT study: Pooled analysis of two noninterventional studies
por: Schöttle, Daniel, et al.
Publicado: (2022)

Monthly Continuous Erythropoietin Receptor Activator Versus Weekly Epoetin-Beta, Similar Hemoglobinization but Different Anisocytosis Degree in Hemodialysis Patients: A Randomized Controlled Trial
por: Uriol-Rivera, Miguel G., et al.
Publicado: (2021)

Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study
por: Canaud, Bernard, et al.
Publicado: (2008)

A fast screening method for the detection of CERA in dried blood spots
por: Rocca, Angela, et al.
Publicado: (2021)

Erythropoietin-producing tubercle granuloma in a hemodialysis patient
por: Satoh, Minoru, et al.
Publicado: (2013)

Obesity may be erythropoietin dose-saving in hemodialysis patients
por: El-Kannishy, Ghada M., et al.
Publicado: (2018)

Erythropoietin treatment and the risk of hip fractures in hemodialysis patients
por: Suresh, Sukanya, et al.
Publicado: (2021)

The Waveform Fluctuation and the Clinical Factors of the Initial and Sustained Erythropoietic Response to Continuous Erythropoietin Receptor Activator in Hemodialysis Patients
por: Liu, Wen-Sheng, et al.
Publicado: (2012)

De la cera a la cerámica : conocinientos básicos para una colaboración eficaz entre técnicos dentales y odontólogos /
por: Montagna, Fabrizio
Publicado: (2008)

Effect of Luting Cements On the Bond Strength to Turkom-Cera All-Ceramic Material
por: Al–Makramani, Bandar M. A., et al.
Publicado: (2018)

Once a month : the original premenstrual syndrome handbook /
por: Dalton, Katharina, 1916-2004
Publicado: (1994)

Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate Among Veterans with Schizophrenia
por: El Khoury, Antoine C, et al.
Publicado: (2021)

Projecting the economic outcomes of switching patients with schizophrenia from oral atypical antipsychotics to once-monthly, once-every-3-months, and once-every-6-months paliperidone palmitate
por: Morrison, Laura, et al.
Publicado: (2023)

Predicting erythropoietin resistance in hemodialysis patients with type 2 diabetes
por: Schneider, Andreas, et al.
Publicado: (2013)

Skeletal muscle mass is associated with erythropoietin response in hemodialysis patients
por: Takata, Tomoaki, et al.
Publicado: (2021)

Erythropoietin Resistance Development in Hemodialysis Patients: The Role of Oxidative Stress
por: Joksimovic Jovic, Jovana, et al.
Publicado: (2022)

Predictors of iron versus erythropoietin responsiveness in anemic hemodialysis patients
por: Hildebrand, Sarah, et al.
Publicado: (2022)

Once-monthly risedronate for postmenopausal osteoporosis
por: Casadei, Kristina, et al.
Publicado: (2010)

Addition of a pontic to all-ceramic Turkom-Cera fixed partial denture restorations
por: Uludag, Bulent, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_odohvalk8u441je8tadm371apl